











1122Reduced-Intensity Allogeneic Hematopoietic Stem Cell
Transplantation for Relapsed Multiple Myeloma
Yvonne A. Efebera,1 Sofia R. Qureshi,1 Suzanne M. Cole,2 Rima Saliba,1 Matteo Pelosini,1
Ronak M. Patel,1 Ebru Koca,1 Floralyn L. Mendoza,1 Michael Wang,2 Jatin Shah,2
Amin Alousi,1 Chitra Hosing,1 Uday Popat,1 Partow Kebriaei,1 Paolo Anderlini,1 Issa F. Khouri,1
Richard Champlin,1 Sergio Giralt,1 Muzaffar H. Qazilbash1Despite recent advances, multiple myeloma (MM) remains incurable, and most patients eventually develop
progressive disease. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially
curative option in 10%-20% of patients with relapsed or refractory disease. We evaluated the outcome of
patients undergoing allo-HSCT with reduced-intensity conditioning (RIC) for relapsed and/or refractory
MM at our institution. The study cohort included 51 patients with heavily pretreated, relapsed MM who
underwent RIC allo-HSCT between 1996 and 2006. The median time from diagnosis to allo-HSCTwas 34
months, and median follow-up in surviving patients was 27 months (range, 3-98 months). Cumulative
transplantation-related mortality at 1 year was 25%. Progression-free survival (PFS) and overall survival
(OS) at 2 years were 19% and 32%, respectively. The incidences of grade II-IV acute and chronic
graft-versus-host disease were 27% and 47%, respectively. At the time of this analysis, 12 patients (24%)
were alive, 7 of whom (14%) were in remission for up to 6 years after allo-HSCT. A lower b2 microglobulin
level (\3.3) and previous autologous HSCTwere predictive of lower nonrelapse mortality and longer PFS
and OS. Our findings indicate that allo-HSCTwith RIC is associated with acceptable toxicity and durable
remission and survival in relapsed or refractory MM. The use of RIC allo-HSCT earlier in the course of
the disease may offer the greatest benefit.
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Multiple myeloma (MM) represents approximately
10% of all hematologic malignancies. The treatment
of newly diagnosed MM has improved remarkably
with the introduction of the novel therapies thalido-
mide, lenalidomide, and bortezomib [1-6]. High-
dose therapy followed by single or tandem
autologous hematopoietic stem cell transplantation
(auto-HSCT) is a treatment option for patients under
the age of 65 years [7,8]. Despite these advances,1Department of Stem Cell Transplantation and Cellular
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6/j.bbmt.2010.02.015however, MM remains incurable, and most patients
develop progressive disease (PD) within 5 years of
auto-HSCT [9].
AllogeneicHSCT (allo-HSCT) offers a potentially
curative option in 10%-20% of patients with relapsed
or refractory MM [10-13], mainly because of
a tumor-free graft and a graft-versus-myeloma
(GVM) effect. The GVM effect has been well docu-
mented and is thought to be mediated by donor-
derived T lymphocytes [10-12]. However, the high
treatment-relatedmortality (TRM)withmyeloablative
(MA) conditioning regimens (up to 55%) neutralizes
any potential benefit in terms of progression-free sur-
vival (PFS) and overall survival (OS), and limits the
use of allo-HSCT in patients with advanced MM
[12,14,15].
Reduced intensity conditioning (RIC) allo-HSCT
offers the potential advantage of decreased TRM,
whereas it preserves the GVM effect [16,17]. Only
limited information is available on the outcomes of
RIC allo-HSCT in patients with advanced and heavily
pretreated MM. In this retrospective single-center
Biol Blood Marrow Transplant 16:1122-1129, 2010 1123RIC Allogeneic Transplantation in Advanced MMstudy, we evaluated the outcomes of RIC allo-HSCT
in 51 heavily pretreated patients with relapsed and/or
refractory disease.PATIENTS AND METHODS
Patients
The study cohort included 51 patients with MM
who had relapsed disease and underwent RIC
allo-HSCT from amatched related or unrelated donor
between 1996 and 2006. Patients were eligible for
allo-HSCT if they were aged 18-70 years and had
a performance status of 0 or 1, adequate organ
function, and no uncontrolled infection.
Hematopoietic Stem Cell Collection
Donor bone marrow (BM) or granulocyte colony-
stimulating factor (G-CSF)–primed peripheral blood
(PB) progenitor cells were collected using standard
mobilization protocols and apheresis techniques. BM
from unrelated donors was obtained through the
National Marrow Donor Program (NMDP) accord-
ing to standard guidelines. All patients provided
written informed consent in accordance with
guidelines of the University of Texas M.D. Anderson
Cancer Center (MDACC) and the NMDP. The study
design was reviewed and approved by the MDACC’s
Institutional Review Board.
Preparative Regimen and Supportive Care
TheRIC regimen consisted of fludarabine (Flu) 90-
120 mg/m2 and melphalan 90-140 mg/m2. The defini-
tion ofRICconditioningwas based onpublished guide-
lines and recommendations [18]. All patients receiving
unrelated donor progenitor cells also received antithy-
mocyte globulin (ATG) as part of their preparative
regimen [19]. Graft-versus-host disease (GVHD) pro-
phylaxis consisted of a combination of tacrolimus and
methotrexate. Patients received infection prophylaxis
with levaquin or ciprofloxacin, voriconazole or flucona-
zole, and acyclovir or valacyclovir. Filgrastim 5 mg/kg
was administered s.c. daily from day 7 after allo-
HSCT until the recovery of absolute neutrophil count
(ANC) to .1.5  109/L for 3 days. Blood products
were irradiated andfiltered to remove leukocytes before
transfusion. After recovery of ANC, patients received
prophylaxis against Pneumocystis jiroveci (formerly Pneu-
mocystis carini) infection with oral sulfamethoxazole-
trimethoprim twice weekly or i.v. pentamidine every 3
weeks.
Engraftment and Chimerism
Engraftment was defined as the first of 3 consecu-
tive days with an ANC $0.5  109/L. Failure to
engraft by day 30 was considered primary graft failure.Platelet engraftment was defined as the first of 7
consecutive days with a platelet count $20  109/L
without transfusion support. PB or BM donor–recipi-
ent chimerismwas performed on days 30 and 100 post-
transplantation, and as clinically indicated thereafter,
through analysis of DNA microsatellite polymor-
phisms by polymerase chain reaction with D6S264,
D3S1282, D18S62, and D3S1300 fluorescence-
labeled primers and through conventional cytogenetic
analysis by G-banding or fluorescent in situ hybridiza-
tion studies for the Y chromosome in sex-mismatched
cases.
Response and Outcome
Response, relapse, and disease progression were
defined based on the international uniform response
criteria for MM [20]. Complete response (CR) was de-
fined as negative immunofixation on the serum and
urine,\5% plasma cells in BM, and absence of any
plasmacytomas or soft tissue lesions. Very good partial
response or major response (VGPR/MR) was serum
and urine monoclonal protein (M-protein) detectable
by immunofixation but not by electrophoresis, or at
least a 90% reduction in serum M-protein, and urine
M-protein\100 mg/24 hours. Partial response (PR)
was defined as at least a 50% reduction of serum
M-protein, at least a 50% reduction in the size of
soft tissue plasmacytomas if present at baseline, and
at least a 90% reduction in 24-hour urinaryM-protein.
Response criteria had to be met on at least 2 assess-
ments at least 6 weeks apart. PD was defined as an
increase in serum M-protein or urine light chains of
$20% in patients with refractory or stable disease
(SD). Relapse was defined the reappearance of serum
M-protein, urine light chains, or BM infiltration in
patients in previous CR, or at least a 25% increase in
any marker in patients in PR. SD was defined as not
meeting the criteria for CR, VGPR, PR, or PD.
Statistical Methods
Primary endpoints were Kaplan-Meier estimates
of OS and PFS. Secondary endpoints were TRM,
relapse, and incidence of acute and chronic GVHD
(aGVHD, cGVHD). OS was measured from the day
of allo-HSCT (day 0) to death from any cause, with
censoring performed at the date of last contact. PFS
was determined from the day of stem cell infusion to
the day of documented relapse or progression. Death
from any cause other than relapse was classified as
TRM. GVHD occurring any time after day 90 post-
transplantation was considered cGVHD; otherwise,
it was aGVHD. Standard criteria were used for the
diagnosis and grading of aGVHD and cGVHD [21].
The incidences of disease progression, TRM,
aGVHD, and cGVHD were estimated using the cu-
mulative incidence method, accounting for competing
Table 1. Patient Characteristics
Age, years, median (range) 51 (32-65)
Females/males, n 24/27




Light chain only 10 (20)
Nonsecretory 2
Unknown 1





Disease status at transplantation, n
(%)
Complete response 2 (4)
Very good partial response 3 (6)
Partial response 23 (45)
Stable disease 14 (27)
Progressive disease 8 (16)
Unknown/not evaluated 1 (2)
Previous regimens, median (range) 5 (1-10)
Previous auto-HSCT, n (%) 36 (70)
One 31
Two 5
Time from diagnosis to allo-HSCT,
months, median (range)
34.4 (9.8-232.2)
HSCT source, n (%)
Peripheral blood 41 (80)
Bone marrow 10 (20)
Donor type, n (%)
Related donor 40 (78)
Unrelated donor 11 (22)
Year of allo-HSCT, n (%)
1996-2000 15 (29)
Beyond 2000 36 (71)
DLIs, n (%) 12 (22)
HSCT indicates hematopoietic stem cell transplantation; DLIs, donor
lymphocyte infusions.
Staging was done according to the Durie-Salmon staging system.
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Analysis was performed using Stata 7.0 (StataCorp,
College Station, TX).RESULTS
Patient Characteristics
Between 1996 and 2006, 51 patients with relapsed
or refractory multiple myeloma underwent allo-






1 2 1.0; 3.85 Persistent disease; P
2 4 Unknown; 0.3; 3.0; unknown Persistent disease; P
3 1 Unknown Persistent disease; P
4 2 Unknown Relapse
5 1 Unknown VGPR
6 1 3.3 PD
7 1 1.4 PD
HSCT indicates hematopoietic stem cell transplantation; DLIs, donor lymphocharacteristics are summarized in Table 1. At the time
of transplantation, 55% of the patients were in at least
partial remission (CR, 4%; VGPR, 6%; PR, 45%).
The median patient age was 51 years (range, 32-65
years), and median time from diagnosis to transplanta-
tion was 34 months (range, 9-232 months). Thirty-six
patients (70%) had undergone previous auto-HSCT,
including 5 (10%) with 2 previous auto-HSCTs. The
median number of previous regimens was 5 (range,
1-10). The stem cell source was PB in 41 patients
(80%) and matched related donor stem cells in 40 pa-
tients (78%). Chromosomal analysis results were avail-
able for 40of the51patients before allo-HSCT.Twelve
patients had cytogenetic abnormalities (3 patients with
13p deletion, 2 patients with 1q abnormality, 2 patients
with 17p deletion and the rest having complex abnor-
malities), and 28 patients had normal cytogenetics.
Engraftment
All 51 patients (100%) achieved engraftment. The
median times to neutrophil and platelet engraftment
were 13 days (range, 9-25 days) and 15 days (range,
10-28 days), respectively. The median percentage of
donor cells at day 30 posttransplantation was 100%
(range, 95%-100%).
Response
Overall, 12 patients (23%) achieved CR and 26
patients (51%) achieved PR, with an overall response
rate of 74% after RIC allo-HSCT. Three patients
(6%) had minimal response (\50%), and 4 patients
(8%) had SD. Two of the 3 patients with a VGPR
before transplantation achieved CR after RIC allo-
HSCT. Of the 23 patients in PR before allo-HSCT,
4 (17%) achieved CR, 1 developed PD, and the rest re-
mained in PR. Of the 14 patients in SD before allo-
HSCT, 3(21%) achieved CR and 7 (50%) achieved
PR/VGPR. Of the 8 patients with PD at allo-HSCT,
1 achieved CR and 3 achieved PR, with an overall
response of 50% in this group. Seven patients who
underwent allo-HSCT from a matched related donor
received a total of 12 donor lymphocyte infusions
(DLIs) for persistent disease, PD, or relapse after
allo-HSCT. One patient with persistent disease
achieved CR, and 1 patient with PD achieved VGPRInterval from





D 391 478 PD
D 97 197 PD






Table 3. Response Rate, TRM, Relapse, and GVHD
Time to neutrophil engraftment, days, median (range) 13 (9-25)
Time to platelet engraftment, days, median (range) 15 (10-28)
100-day TRM, n (%) 6 (12)
Cumulative 1-year TRM, n (%) 13 (25)
Overall response rate 74% (CR,
23%; PR, 51%)
Relapse at 2 years, n (%) 25 (49)
Median PFS, months 6.8
2 year PFS, % 19
Median OS, months 13.9
2-year OS, % 32
Acute GVHD grade II-IV, n (%) 14 (27)
Chronic GVHD, limited or extensive, % 47%
Deaths, n (%) 39 (76)
Disease recurrence 22 (43)
Acute or chronic GVHD 10 (20)
Infection 3 (6)
Other 4 (8)
TRM indicates treatment related mortality; GVHD, graft-versus-host
disease; PFS, progression-free survival; OS, overall survival.
Biol Blood Marrow Transplant 16:1122-1129, 2010 1125RIC Allogeneic Transplantation in Advanced MMafter a single DLI; the rest had no response. Table 2
summarizes cell doses, intervals between HSCT and
DLI, intervals between DLIs, and responses.GVHD
The cumulative incidence of grade II-IV aGVHD
was 27% (Table 3). Grade II aGVHD was seen in
16%; grade III-IV aGVHD, in 11%. The cumulative
incidence of cGVHD was 47%, with limited cGVHD
seen in 23% of patients. The use of unrelated donor or
PB stem cells (PBSCs) as the graft source did not in-
crease the incidence of aGVHD or cGVHD, possibly
due to the small number of patients with unrelated
donors (n 5 11) and BM stem cells (n 5 10).Figure 1. PFS and OS of patientsTRM
The 100-day TRMwas 12%, and the 1-year TRM
was 25%. At the time of this analysis, 12 patients (24%)
were still alive; of these, 7 (14%) had been in remission
for up to 6 years after allo-HSCT. The most common
causes of death were recurrent disease (22 patients;
43%), aGVHD or cGVHD (10 patients; 20%), and
opportunistic infections (3 patients; 6%) (Table 3).Survival and Prognostic Features
The median follow-up for surviving patients was
27 months (range, 3-98 months). Twenty-five patients
(49%) had relapsed at 2 years. Seven patients had
received a total of 12 DLIs. The use of DLI did not
contribute to improved PFS and OS on multivariate
and univariate analyses, perhaps because of the small
number of patients who received DLI. The 2-year
PFS and OS were 19% and 32%, respectively
(Figure 1). On univariate analyses, a lower b2 micro-
globulin (\3.3mg/L) and previous auto-HSCT pre-
dicted longer PFS and OS (Table 4). These 2 factors
also emerged as predictors of longer PFS and OS on
multivariate analysis (Table 5). Age, immunoglobulin
subtype, serum lactate dehydrogenase (LDH) level, se-
rum albumin level, stem cell source, donor type, use of
DLI, interval between diagnosis and allo-HSCT, and
interval between auto-HSCT and allo-HSCT did
not emerge as statistically significant predictors of
outcome.
The major differences between the long-term
survivors (12 patients) and others were a lower b2
microglobulin level (median, 2.45 vs 3.5; P 5 .01) andundergoing RIC allo-HSCT.
Table 4. Univariate Factors Affecting NRM, PFS, and OS in the RIC Group
NRM OS PFS
Pre-HSCT Factors HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age at HSCT, years
#50
>50 0.3 (0.1-1.6) .2 0.8 (0.4-1.7) .6 0.8 (0.4-1.5) .4
IgG(mg/dL)
#1600
>1600 1.1 (0.2-5.5) .9 1.4 (0.7-2.9) .3 1.4 (0.7-2.8) .3
b2m(mg/L)
#3.3
>3.3 7 NRM .01 3.1 (1.5-6.4) .002 2.6 (1.3-5.1) .005
LDH(U/L)
#618
>618 0.5 (0.1-4.6) .6 0.7 (0.3-1.8) .5 0.9 (0.4-1.9) .8
Albumin(g/dL)
#3.5
>3.5 0.6 (0.1-2.6) .5 0.7 (0.3-1.4) .3 0.7 (0.4-1.4) .4
Response pre-HSCT
CR/PR 0.7 (0.2-3.2) .6 1.1 (0.6-2.2) .7 1.1 (0.6-2.1) .7
Other
Cytogenetics pre-HSCT
High risk 1.9 (0.4-11) .4 2.1 (0.9-4.7) .08 1.8 (0.8-3.9) .1
Other
Previous auto-HSCT
No 17 (2.0-142) .009 2.2 (1.1-4.5) .03 1.8 (0.9-3.4) .08
Yes
Donor type
Related 0.3 (0.1-1.5) .1 0.7 (0.3-1.6) .5 0.9 (0.4-1.9) .9
Unrelated
Graft source
Peripheral blood 1.5 (0.2-12) .7 0.9 (0.4-2.1) .9 1.1 (0.5-2.3) .9
Bone marrow
Months from diagnosis to HSCT
#24
>24 0.4 (0.1-1.8) .2 0.5 (0.2-1.1) .07 0.6 (0.3-1.1) .1
Months from auto-HSCT to allo-HSCT
#24
>24 0.9 (0.3-2.1) .8 0.6 (0.3-1.4) .2
NRM indicates nonrelapse mortality; PFS, progression-free survival; OS, overall survival; RIC, reduced intensity conditioning; LDH, lactate dehydroge-
nase; HSCT, hematopoietic stem cell transplantation; CR, complete response; PR, partial response.
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the long-term survivor group (Table 6).DISCUSSION
Despite recent progress in the treatment of MM,
the disease remains incurable. The response duration
decreases with each successive relapse and salvage, re-
flecting acquired drug resistance. Before the advent of
novel therapies, event-free survival (EFS) was 7
months for patients undergoing a second-line regimen
and 3 months for those undergoing a sixth-line regi-
men [22]. Novel therapies have improved this dismal
outcome. In 289 relapsed patients who had received
thalidomide, lenalidomide, or bortezomib at some
point after relapse, the median and 2-year OS were
23.9 months and 49%, compared with 11.8 months
and 24% in 98 patients who had not received these
drugs at relapse [6]. Despite this improvement, how-
ever, EFS inmost patients with persistent or refractory
disease is only 6-14 months [23-26]. These numbershighlight the need for more effective therapy,
especially in patients with good performance status.
Allografting is a potentially curative option for
selected patients with relapsed or refractory multiple
myeloma, in part because of a tumor-free graft and
a GVM effect [10-12,27,28]. The increased TRM
achieved using MA regimens offsets any improvement
in EFS and OS [12,14,15,29]. Randomized studies
using RIC allo-HSCT in combination with autologous
transplant (auto-RIC allo-HSCT) have been per-
formed mainly in newly diagnosed patients with
a matched related donor [30-32]. These studies
compared tandem auto-HSCT and auto-RIC allo-
HSCT. Although the auto-RIC allo-HSCT group
had a higher rate of CR, 2 of the 3 studies found no
difference in EFS andOS between the 2 groups, mainly
because of increased TRM [30,32]. The discrepant
results might be explained by differences in study
design. In the Spanish trial, only patients failing to
achieve nearCR after a first auto-HSCTwere included,
and the conditioning regimen comprised Flu and
melphalan [30]. In the Italian study, all patients were
Table 5. Multivariate Factors Affecting OS and PFS in the
RIC Group
OS PFS
Factors HR (95% CI) P HR (95% CI) P
b2m
#3.3
>3.3 3.3 (1.6-6.9) .002 2.7 (1.4-5.3) .004
Previous auto-HSCT
No 2.8 (1.3-5.9) .01 1.9 (0.9-3.9) .06
Yes
OS indicates overall survival; PFS, progression-free survival.






Age, years, median (range) 51 (32-55) 52 (41-65)
Females/males 6/6 18/21
Immunoglobulin class, n (%)
IgG 6 (50) 23 (59)
IgA 2 (17) 6 (15)
IgM 1 0
Light chain only 3 (25) 7 (18)
Nonsecretory 0 2
Unknown 0 1
Stage at initial diagnosis, n (%)
I 0 5 (19)
II 4 (33) 10 (25)
III 7 (58) 23 (59)
Unknown 1 1
Cytogenetics
Normal 4 (33) 24 (62)
13p deletion 0 3 (8)
1q abnormality 0 2 (5)
17p deletion 0 2 (5)
Other 3 2
Unknown 5 6
B2m, median (range) 2.45 (1.8-4.9) 3.5 (1.0-8.2)
Disease status at HSCT, n (%)
CR 2 (17) 0
VGPR 1 (8) 2 (5)
PR 4 (33) 19 (49)
SD 2 (17) 12 (31)
PD 2 (17) 6 (15)
Unknown/not evaluated 1 0
Previous regimens, n, median (range) 5 (2-10) 5 (1-10)
Previous auto-HSCT, n (%) 11 (92) 25 (64)
One 8 23
Two 3 2
Performance status 0-1 0-1
Time from diagnosis to
allo-HSCT, months,
median (range)
40.2 (19.8-89.1) 34.0 (9.8-232.2)
HSCT source, n (%)
Peripheral blood 9 (75) 32 (82)
Bone marrow 3 (25) 7 (18)
Donor type, n (%)
Related donor 9 (75) 31 (79)
Unrelated donor 3 (25) 8 (21)
Year of allo-HSCT, n (%)
1996-2000 2 (17) 13 (33)
Beyond 2000 10 (83) 26 (66)
DLIs, n (%) 2 (17) 10 (25)
CR indicates complete response; PR, partial response; VGPR,very good
partial response; SD, stable disease; PD, progressive disease; HSCT,
hematopoietic stem cell transplantation; DLIs, donor lymphocyte
infusions.
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status after a first auto-HSCT, and the conditioning
regimen was 2 Gy total body irradiation [31]. In the
French study, only patients with high-risk features (b2
microglobulin .3 mg/L and 13q- deletion) were
included, and the conditioning regimen comprised
busulfan, Flu, and ATG [32]. The high TRM was
attributed to profound immunosuppression from the
previous auto-HSCT,whichwas exacerbatedbyoppor-
tunistic infections and GVHD resulting from RIC
allo-HSCT. Given the lack of an unequivocal benefit,
the role of RIC allo-HSCT in front-line therapy is
considered experimental, and these transplantations
should be performed only as part of well-designed
clinical trials in the highest-risk patients [33].
Retrospective studies of RIC allo-HSCT for
relapsed or refractory MM have demonstrated de-
creased TRM with maintenance of the GVM effect
[16,17,34-37]. Most of these reports were based on
a small number of patients, however, with the
exception of a European Group for Blood and
Marrow Transplantation (EBMT) study [16]. That
study included 229 patients who underwent RIC
allo-HSCT, of whom 168 were beyond first remission
and 169 had undergone previous auto-HSCT. TRM
was 11% at 100 days and 22% at 1 year. The response
rate (CR1 PR) was 73%, and 3-year OS and PFS were
41% and 21%, respectively. Ninety-three patients
(41%) relapsed or progressed; 80 of these patients
went on to receive DLI, with 63% obtaining CR or
PR after DLI [16]. Other studies conducted with
much smaller sample sizes (19-45 patients) have
yielded similar TRM and response outcomes. Poor
prognostic factors for outcome included chemoresist-
ant disease, disease beyond first remission, more than
one previous auto-HSCT, and a $1-year interval
between diagnosis and HSCT [16,34].
In our study, the 100-day TRM was 12% and the
1-year TRM was 25%, comparable to the percentages
found in the EMBT series [16]. The response rate was
74% (CR, 23%; PR, 51%), similar to what was seen in
previous studies [16,17,34]. The incidence of GVHD
was not adversely affected by the use of unrelated
donors or PBSCs. This might be attributed to theuse of high-resolution molecular HLA typing and
the use of ATG for GVHD prophylaxis [19]. The
2-year OS was 32%, comparable to that found in
previous series, although our patients generally had
more advanced disease.
We emphasize that compared with the EBMT
study, the patients in our series were more heavily pre-
treated and had a longermedian time from diagnosis to
allo-HSCT (34 months vs 18 months). Age, immuno-
globulin subtype, disease status, serum LDH, serum
albumin, stem cell source, donor type, use of DLI,
interval between diagnosis and allo-HSCT, or interval
1128 Biol Blood Marrow Transplant 16:1122-1129, 2010Y. A. Efebera et al.between auto-HSCT and allo-SCT did not emerge as
statistically significant predictors of outcome. We rec-
ognize that some of these analyses suffer from the
known limitations of a retrospective analysis, including
small sample size, heterogeneous patient population,
andmissing data. The ongoing multicenter BoneMar-
row Transplant-Clinical Trial Network (BMT-CTN)
BMT-CTN trial comparing tandem auto-HSCTwith
and without maintenance therapy versus single auto-
HSCT followed by RIC allo-HSCT in patients with
newly diagnosed MM will help define the role of
RIC allo-HSCT in this patient population.
In conclusion, our data indicate that allo-HSCT
after RIC regimens in selected patients with advanced
MM is associated with durable PFS andOS and a lower
TRM compared with allo-HSCT after MA regimens.
RIC regimens in patients with advanced MM do not
increase the risk of relapse or the incidence of aGVHD
and cGVHD. The application of RIC allo-HSCT
earlier in the course of the disease may be of greater
benefit in selected patients.ACKNOWLEDGMENTS
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